BioCentury
ARTICLE | Company News

Antisoma, Institute of Cancer Research deal

October 13, 2008 7:00 AM UTC

Antisoma received worldwide, exclusive rights to develop and commercialize the institute's inhibitors of protein phosphatase magnesium-dependent 1 delta (PPM1D, WIP1) to treat cancer. The company an...